Aristo Pharma Nordic ApS: Financial statements 2016
CVR: 32328768
Source: annual report 2016, Danish Business Authority
01/01/2016 – 31/12/2016
Aristo Pharma Nordic ApS (CVR 32328768) has filed annual accounts for 2016. In 2016, the company reported a gross profit of EUR -474,855 and a net result of EUR -2,070,042 compared with EUR -1,602,082 the year before. Equity in the 2016 report amounted to EUR -4,731,382. The company had 12 employees in the financial year.
- Gross Profit
- EUR -474,855
- Profit/Loss
- EUR -2,070,042
- Equity
- EUR -4,731,382
- Total Assets
- EUR 6,210,990
- Employees
- 12
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | - | -475 t. EUR | -2.1 mio. EUR | -4.7 mio. EUR | 12 |
| 2015 | - | 145 t. EUR | -1.6 mio. EUR | -2.7 mio. EUR | 11 |
| 2014 | - | -734 t. EUR | -1.7 mio. EUR | -1.1 mio. EUR | 12 |
| 2012 | - | -297 t. | -428 t. | -484 t. | - |
Official annual report
Find more companies like Aristo Pharma Nordic ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2016
As of December 16, 2016, János Váczi is registered as director of Aristo Pharma Nordic ApS.
As of December 16, 2016, Lena Storm Christensen has stepped down as director of Aristo Pharma Nordic ApS.
Aristo Pharma Nordic ApS has published its annual report for 2015. Gross profit came to DKK 145,002, and the net result was DKK -1,602,082.
About Aristo Pharma Nordic ApS
Aristo Pharma Nordic ApS is a Danish company of the type Anpartsselskab based in Skovlunde, founded in 2011. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named AMNEAL NORDIC ApS and COPHARMA ApS. The management consists of John Hudson Kriwet. The board consists of John Hudson Kriwet (chair), Jannes Paul Beeskow and Robert Maciej Szymanski. The company is owned by Aristo Pharma GmbH. The company has 1 employee (2026). In 2025, the company reported revenue of EUR 453,392 and a net result of EUR 21,589 compared with EUR 25,190 the year before. Equity in the 2025 report amounted to EUR 184,874.